

Health technology assessment for academic ATMPs

Three scenarios

Jakob Wested, Associate professor
EU Pharmaceutical Law
Center for Advanced studies in Bioscience
Law (CeBIL)

KØBENHAVNS UNIVERSITET



MUNI | CREATIC

Central European Advanced
Therapy and Immunotherapy Centre

„CREATIC as the flagship in CEE region, provides excellent research of gene and somatic cell therapy to deliver safe, accessible and affordable personalised treatment of life-threatening or chronically debilitating rare disease patients that are conventionally considered incurable.“



UNIVERSITÄT
LEIPZIG

UNIVERSITY OF
COPENHAGEN




MUNI | CREATIC

Central European Advanced
Therapy and Immunotherapy Centre

MUNI

What is the problem(s)?



What is the problem(s)?

market Access tied to market Approval



Experience




Evidence




Economy

Route to patients "conventional medicinal products"



Route to patients for Academic ATMPs



Three routes for Academic ATMP's

Spin-Out


ATMP is sold or licensed to a company that continues its development towards MA

"Classic tech-transfer"
- feasibility?

Spin-in

Academic institution pursues a Marketing authorization for the ATMP

Organisational competences?
Priorities?



Spin-around

ATMP use by the academic institution continues without a marketing authorization

Duplication of efforts?
Sustainability?
access?



